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Efficacy and safety data of interferon-free regimens in hepatitis C (HCV) 
genotype 4(G4) patients are scarce. In Belgium, Sofosbuvir (SOF) and 
Simeprevir (SIM)  treatment are available since January 2015 for G1 and 
G4 patients with advanced fibrosis (F3-F4 METAVIR) for 12 weeks. 
The aim of the study was to evaluate the safety and efficacy of this 
treatment 
Patients and Methods 
75 G4 patients were enrolled in this data collection including 41.3% with severe 
fibrosis (F3) and 58.7% cirhotic patients definied by histology or non invasive tests 
of liver fibrosis. 
     Results 
1.Patients characteristics 
75 patients 
Median age (years) 59 [30-81] 




F3/F4 (%) 41,3/58,7 
Ribavirine treatment (%) 36 
HIV coinfection (%) 10,5 
Median ALT (UI/mL) 66[25-327] 
Median bilirubine (mg/mL) 0,77 [0,10-5,70] 
Median INR 1,1 [0,9-2,16] 
Median platelet level (10³/mm³) 123 [23-320] 
Albumin (g/L) 39,3 [24,5-58] 
Ascites (cirrhosis) (%) 4,8 
Encephalopathy (cirrhosis) (%) 2,5 
MELD (cirrhosis) 9 [6-19] 
Child-Pugh (cirrhosis) 5 [5-9] 
Treatment duration 12W/24W 73/2 


























































































No serious adverse event related to the treatment was observed.  
Among patients treated with and without RBV, 
4,17% and 4,56% had hemoglobin <10g/dL at W4  
and 0% and 2,26% at W12, respectively. Conclusions 
Sofosbuvir in combination with Simeprevir +/- ribavirin in G4 HCV patients with advanced fibrosis 
achieved high SVR12 rates and was well tolerated.  
Relapses were only observed in cirrhotic patients with advanced disease. 
Background and aim 
HCV RNA at week 4 of treatment, at the end of treatment (EOT) 
and at week12 after de end of treatment for all the population: 
Sustained virological response (SVR) 12: 93,6% 
HCV RNA at week 4 of treatment, at the end of treatment (EOT) 
and at week 12 after the end of treatment in patients treated without  
and with ribavirin: SVR12: 93,1% and 94,4% respectively 
HCV RNA at week 4 of treatment, at the end of treatment (EOT)  
and at week 12 after the end of treatment according to the degree of fibrosis: 
SVR12: 100% and 88,9% for F3 and cirrhosis respectively. 
Patient 1 Patient 2 Patient 3 
Cirrhosis Yes Yes  Yes 
Ribavirin No Yes No 
Treatment 
experienced 
No Yes Yes 
Age 41 56 49 
Sex M M F 
MELD 19 13 11 
Child-Pugh 9 8 5 
Platelet 100 42 35 
Albumin 28 24,5 36,3 
W0 HCV RNA 2282346 9160000 
W4 HCV RNA 31 ND 383 
W12 HCV RNA ND ND ND 
Characteristics of the patients who have relapsed 
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2. Virological response 
